Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Q1 2026 results released for quarter ended March 31, 2026.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results released for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
- Investor focus: quarterly operating performance, liquidity, and financial condition disclosed in the exhibit
Item 7.01 · Regulation FD Disclosure
- Phase III AFFINITY DUCHENNE trial presented topline and interim RGX-202 data on May 14, 2026
- Pivotal-stage data may influence RGX-202’s regulatory trajectory and commercial outlook
- Investors should review presentation materials on REGENXBIO’s website for efficacy and safety details
Item 8.01 · Other Events
- REGENXBIO announced topline and interim AFFINITY DUCHENNE RGX-202 trial data on May 14, 2026
- Clinical update creates a potential valuation catalyst for RGX-202 and REGENXBIO’s Duchenne muscular dystrophy program
- Detailed efficacy and safety findings are in Exhibit 99.2, requiring review for investment implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.